Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
8 July 2024 |
Main ID: |
EUCTR2020-000597-26-PL |
Date of registration:
|
16/09/2020 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and
efficacy of Crovalimab versus Eculizumab in Adult and Adolescent Patients
with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated with
Complement Inhibitors.
|
Scientific title:
|
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED,
MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS,
PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS
ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT
INHIBITORS |
Date of first enrolment:
|
23/11/2020 |
Target sample size:
|
190 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000597-26 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Belgium
|
Brazil
|
Colombia
|
Czech Republic
|
Czechia
|
Estonia
|
France
|
Germany
|
Greece
|
Hong Kong
|
Hungary
|
Ireland
|
Israel
|
Italy
|
Japan
|
Korea, Republic of
|
Mexico
|
Netherlands
|
Philippines
|
Poland
|
Portugal
|
Spain
|
Sweden
|
Taiwan
|
Thailand
|
Türkiye
|
United Kingdom
|
United States
| | | |
Contacts
|
Name:
|
Trial Information Support Line-TISL
|
Address:
|
Grenzacherstrasse 124
4070
Basel
Switzerland |
Telephone:
|
|
Email:
|
global.rochegenentechtrials@roche.com |
Affiliation:
|
F. Hoffmann-La Roche Ltd |
|
Name:
|
Trial Information Support Line-TISL
|
Address:
|
Grenzacherstrasse 124
4070
Basel
Switzerland |
Telephone:
|
|
Email:
|
global.rochegenentechtrials@roche.com |
Affiliation:
|
F. Hoffmann-La Roche Ltd |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: General Inclusion Criteria (All Patients) - Body weight >= 40 kg - Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry evaluation of WBCs, - Vaccination against Neisseria meningitidis serotypes A, C, W, and Y < 3 years prior to initiation of study treatment, or, if not previously done, vaccination administered no later than one week after the first drug administration. Vaccination currency should be maintained throughout the study in accordance with most current local guidelines or standardof- care as applicable in patients with complement deficiency - Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae according to national vaccination recommendations - Platelet count >= 30,000/mm*3 at screening without transfusion support within 7 days of lab testing. - ANC > 500/micro L at screening - For female patients of childbearing potential: agreement to remain abstinent or use contraception For Patients in Randomized Arms (Arm A and B) - Age >= 18 years - Documented treatment with eculizumab according to the approved dosing recommended for PNH and completion of a minimum of 24 weeks of treatment prior to Day 1 - Lactate dehydrogenase (LDH) <= 1.5 × ULN at screening For Patients in Non Randomized Arm (Arm C) - Age <18 old, currently treated with eculizumab OR - Currently treated with ravulizumab OR - Currently treated with eculizumab at higher-than-approved doses OR - Patients with known C5 polymorphism and poorly controlled hemolysis by eculizumab or ravulizumab - Adult patients currently treated with approved doses of eculizumab LDH <= 1.5 × ULN at screening
Are the trial subjects under 18? yes Number of subjects for this age range: 3 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 152 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 35
Exclusion criteria: - Major Adverse Vascular Event within 6 months prior to first drug administration (Day 1) - History of allogeneic bone marrow transplantation, - Neisseria meningitidis infection within 6 months prior to screening and up to first study drug administration - History of myelodysplastic syndrome with Revised International Prognostic Scoring System (IPSS-R) prognostic risk categories of intermediate, high and very high - Pregnant or breastfeeding, or intending to become pregnant during the study or within 46 weeks (approximately 10.5 months) after the final dose of crovalimab, or 3 months after the final dose of eculizumab (or longer if required by the local product label) - Concurrent disease, treatment, procedure, or surgery or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the patient, or would, in the opinion of the Investigator, preclude the patient's safe participation in and completion of the study - Splenectomy <= 6 months prior to screening - Positive for hepatitis B surface antigen at screening - Positive for hepatitis C virus antibody at screening confirmed by detectable HCV RNA - History of or ongoing cryoglobulinemia at screening
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) MedDRA version: 21.1
Level: PT
Classification code 10034042
Term: Paroxysmal nocturnal haemoglobinuria
System Organ Class: 10038359 - Renal and urinary disorders
|
Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
|
Intervention(s)
|
Product Name: Crovalimab Product Code: RO7112689/F03-01 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: CROVALIMAB Current Sponsor code: RO7112689 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 170-
Trade Name: Soliris Product Name: Eculizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ECULIZUMAB CAS Number: 219685-50-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-
Product Name: Crovalimab Product Code: RO7112689/F03-10 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: CROVALIMAB Current Sponsor code: RO7112689 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 170-
|
Primary Outcome(s)
|
Secondary Objective: • To characterize the crovalimab, eculizumab, and ravulizumab pharmacokinetics profile • To evaluate the immune response to crovalimab • To identify and/or evaluate biomarkers that can potentially provide evidence of crovalimab, eculizumab, and ravulizumab activity • To evaluate the efficacy of crovalimab compared with eculizumab
|
Main Objective: To evaluate the safety and tolerability of crovalimab compared with eculizumab
|
Primary end point(s): 1. Incidence and severity of adverse events 2. Change from baseline in targeted vital signs 3. Change from baseline in targeted clinical laboratory test results 4. Incidence and severity of injection-site reactions, infusion-related reactions, hypersensitivity, and infections 5. Incidence of adverse events leading to study drug discontinuation 6. Incidence and severity of clinical manifestations of drug-target-drug complex formation in patients who switched to crovalimab treatment from eculizumab or ravulizumab treatment
|
Timepoint(s) of evaluation of this end point: 1. Up to 8 years 2-3. From baseline to 8 years 4-5. Up to 8 years 6. From baseline to 8 years
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: 1. Up to 8 years (crovalimab) and up to Week 25 (eculizumab) 2. At baseline 3. At baseline (prevalence) and up to 8 years (incidence) 4-6. Up to 8 years 7. From Baseline to Weeks 21, 23, 25 8-11. From Baseline to Week 25
|
Secondary end point(s): 1. Serum concentration of crovalimab or eculizumab 2. Serum concentration of ravulizumab 3. Prevalence and incidence of anti-drug antibodies (ADAs) to crovalimab 4. Change over time in pharmacodynamic biomarkers 5. Change over time in free C5 concentration in crovalimab-treated patients 6. Observed value and absolute change in parameters reflecting hemolysis 7. Percent change from baseline in LDH level averaged over Weeks 21, 23, and 25 LDH measurements 8. Proportion of patients with transfusion avoidance 9. Proportion of patients with breakthrough hemolysis 10. Proportion of patients with stabilization of hemoglobin 11. Mean change in fatigue as assessed through use of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale
|
Secondary ID(s)
|
2020-000597-26-SE
|
BO42161
|
Source(s) of Monetary Support
|
F.Hoffman-La Roche Ltd
|
Chugai Pharmaceutical Co. Ltd
|
Ethics review
|
Status: Approved
Approval date: 29/09/2020
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|